Provenge Extends Survival of mCRPC Patients By Up to 4 Years, Data Show

Provenge Extends Survival of mCRPC Patients By Up to 4 Years, Data Show
Treatment with the immunotherapy Provenge (sipuleucel-T) in a real-world setting is showing  similar safety and efficacy in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) as in clinical trials, a study shows. The observational registry study — called PROCEED (NCT01306890) — conducted at urology and medical oncology clinics showed that men with lower prostate specific antigen (PSA) levels at baseline lived nearly four years after receiving Provenge. “The median survival of four years following treatment with PROVENGE is meaningful,” Celestia S. Higano, MD, FACP, lead author of the PROCEED analysis, said in a press release. The study, “Real-world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer,” was published in the journal Cancer. Provenge, marketed by Dendreon Pharmaceuticals, is an immunotherapy that uses a patient’s own immune cells to fight prostate cancer. In it, a fraction of white blood cells that have been exposed to a prostate cancer protein are primed to activate the remaining immune cells to fight cancer. In 2010, Provenge became the first immunotherapy approved for metastatic prostate cancer in the United States after it significantly extended patients' lives by four months in the IMPACT Phase 3 trial (NCT00065442). Since then, and because prostate cancer management is rapidly changing, researchers designed PROCEED to study the safety and efficacy of mCRPC treatment protocols involving Provenge in a real-world setting. PROCEED enrolled 1,976 mCRPC patients across 140 community clinics and 52 academic sites. Patients were very similar to those included in IMPACT, with a somewhat worse
Subscribe or to access all post and page content.